Chembio Diagnostics Announces Agreement with Bio-Manguinhos to Commercialize Point-of-Care Tests for Dengue, Zika and Chikungunya in Brazil
Bio-Manguinhos is a unit of the
In 2016, Chembio announced a collaboration with Bio-Manguinhos to develop POC tests for Dengue, Zika and Chikungunya, as both standalone and multiplex tests. Since that time, using Chembio's patented DPP® technology platform, which detects antibodies in less than 15 minutes using a tiny (10uL) drop of blood from the fingertip, Chembio has accomplished:
- Development of new point-of-care DPP® tests for Dengue, Zika, and Chikungunya as both standalone and multiplex tests.
- Clinical testing of the new DPP® tests and DPP® Micro Reader in numerous regions, including
the United States, Africa, Latin Americaand Southeast Asia.
- Regulatory approval for the DPP® Zika System, including Brazil Agência Nacional de Vigilância Sanitária approval, U.S. Food and Drug Administration Emergency Use Authorization, and CE mark.
- A conditional agreement from
UNICEFfor purchases of the Company's DPP® Zika System, which includes a purchase commitment of $1.5 millionand possible additional purchases of up to $3.4 million.
"We are pleased to announce a long-term agreement with Bio-Manguinhos, which is an important step toward commercializing the DPP® Dengue, Zika and Chikungunya tests in
The Company markets its products directly and through third-party distributors under the brand names: DPP®, STAT-PAK®, SURE CHECK®, and STAT-VIEW®.
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the
Investor Relations Contact
Source: Chembio Diagnostics, Inc.